Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.

Author: m.nasser

Working with Innovest has been a great experience for Rawabi Farah. Their professional approach, innovative solutions, and commitm...

Rawabi Farah

Partnering with Innovest has been a game-changer for us at Mais Irrigation. Their professional approach, attention to detail, and ...

Partnering with Innovest has been a game-changer for us at Mais Irrigation. Their professional approach, attention to detail, and ...

Aljazeera Hospital